IDXX
IDEXX Laboratories, Inc. · Healthcare · Medical - Diagnostics & Research
Momentum inputs (comparable managers):
holder breadth -5.6% ·
share flow +1.4% ·
net new positions -5.9%
· formula
Concentrated accumulation: rising shares among fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q4 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 7 | 0 | 471.56K | $245.77M | n/a | n/a |
| Q2 2026 | 168 | 0 | 55.55M | $29.26B | +7 | −6 |
| Q1 2026 | 170 | +1 | 53.67M | $30.16B | +5 | −5 |
| Q4 2025 | 168 | +2 | 58.18M | $39.32B | +3 | n/a |
| Q3 2025 | 21 | +1 | 29.88M | $19.09B | +1 | −1 |
| Q2 2025 | 18 | 0 | 26.38M | $14.14B | +1 | −1 |
| Q1 2025 | 15 | -2 | 9.43M | $3.96B | n/a | −2 |
| Q4 2024 | 17 | -1 | 9.47M | $3.92B | n/a | −1 |
| Q3 2024 | 17 | +1 | 5.70M | $2.88B | +1 | n/a |
| Q2 2024 | 16 | n/a | 5.12M | $2.49B | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | State Street Global Advisors ✦ (passive) | 3.64M | n/a | $1.50B | 0.1% | n/c | 1 | SEC ↗ |
| 2 | Geode Capital Management ✦ (passive) | 2.30M | +1.7% | $948.28M | 0.1% | ▲ Add | 3 | SEC ↗ ×2 |
| 3 | T. Rowe Price ✦ | 1.16M | -24.3% | $480.81M | 0.1% | ▼ Trim | 3 | SEC ↗ ×2 |
| 4 | Norges Bank ✦ (passive) | 997.14K | -0.2% | $412.26M | 0.1% | ▼ Trim | 3 | SEC ↗ |
| 5 | Millennium Management ✦ | 256.23K | +64.5% | $105.93M | 0.1% | ▲ Add | 3 | SEC ↗ |
| 6 | D. E. Shaw & Co. ✦ | 212.14K | +68.1% | $87.71M | 0.1% | ▲ Add | 3 | SEC ↗ ×2 |
| 7 | Marshall Wace ✦ | 207.11K | +632.5% | $85.63M | 0.1% | ▲ Add | 3 | SEC ↗ ×2 |
| 8 | Wellington Management ✦ | 195.37K | +161.2% | $80.77M | 0.0% | ▲ Add | 3 | SEC ↗ ×4 |
| 9 | Arrowstreet Capital ✦ | 142.19K | +6.5% | $58.79M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 10 | AQR Capital Management ✦ | 122.68K | +133.6% | $50.72M | 0.1% | ▲ Add | 3 | SEC ↗ ×4 |
| 11 | Two Sigma Investments ✦ | 87.49K | -21.7% | $36.17M | 0.1% | ▼ Trim | 3 | SEC ↗ |
| 12 | Citadel Advisors ✦ | 78.05K | +237.9% | $32.27M | 0.0% | ▲ Add | 3 | SEC ↗ ×2 |
| 13 | Adage Capital Partners ✦ | 28.97K | -14.7% | $11.98M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 14 | Renaissance Technologies ✦ | 25.00K | -30.0% | $10.34M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 15 | Gotham Asset Management ✦ | 13.76K | -28.9% | $5.69M | 0.1% | ▼ Trim | 3 | SEC ↗ |
| 16 | Bridgewater Associates ✦ | 8.86K | -30.5% | $3.66M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 17 | Fisher Asset Management ✦ | 697 | +2.8% | $288,564 | 0.0% | ▲ Add | 3 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| Point72 Asset Management | $48.73M | was 0.2% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 1,302 holders, 70.72M shares, $38.50B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Director · 2.20K sh · $1.17M
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology